Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study

被引：0

作者：

Jianqiu Wu

Yongping Song

Liping Su

Li Xu

Tingchao Chen

Zhiyun Zhao

Mingzhi Zhang

Wei Li

Yu Hu

Xiaohong Zhang

Yuhuan Gao

Zuoxing Niu

Ru Feng

Wei Wang

Jiewen Peng

Xiaolin Li

Xuenong Ouyang

Changping Wu

Weijing Zhang

Yun Zeng

Zhen Xiao

Yingmin Liang

Yongzhi Zhuang

Jishi Wang

Zimin Sun

Hai Bai

Tongjian Cui

Jifeng Feng

机构：

[1] Jiangsu Cancer Hospital,

[2] Henan Cancer Hospital,undefined

[3] Shanxi Cancer Hospital,undefined

[4] Shanghai Roche Pharmaceuticals Ltd,undefined

[5] The First Affiliated Hospital of Zhengzhou University,undefined

[6] Jilin University First Affiliated Hospital,undefined

[7] Union Hospital Tongji Medical College Huazhong University of Science and Technology,undefined

[8] The Second Affiliated Hospital of Zhejiang University School of Medicine,undefined

[9] Fourth Hospital of Hebei Medical University,undefined

[10] Affiliated Hospital of Shandong Academy of Medical Sciences,undefined

[11] Nanfang Medical University Nanfang Hospital,undefined

[12] Guangdong Foshan First Hospital,undefined

[13] Guangdong Zhongshan People’s Hospital,undefined

[14] Xiangya Hospital Central South University,undefined

[15] Fuzhou General Hospital of Nanjing Military Command,undefined

[16] Changzhou First People’s Hospital,undefined

[17] 307 Hospital of PLA,undefined

[18] First Affiliated Hospital of Kunming Medical University,undefined

[19] Affiliated hospital of Neimenggu Medical College,undefined

[20] The Fourth Military Medical University Affiliated Tangdu Hospital,undefined

[21] Daqing General Hospital Group Oilfield General Hospital,undefined

[22] Affiliated Hospital of Guiyang Medical College,undefined

[23] Anhui Provincial Hospital,undefined

[24] Lanzhou Military Hospital,undefined

[25] Fujian provincial hospital,undefined

来源：

BMC Cancer | / 16卷

关键词：

DLBCL; R-CHOP; Chemotherapy; HBV infection; HBsAg;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and Meta-Analysis
Ren Yuan-Rong
Jin Yong-Dong
Zhang Zhi-Hui
Li Li
Wu Ping
中华医学杂志英文版, 2015, 128 (03) : 378 - 383
[22] CaboCombo: A prospective international non-interventional study of first-line cabozantinib plus nivolumab for the treatment of patients with advanced renal cell carcinoma.
Barthelemy, Philippe
Dutailly, Pascale
Qvick, Bryan
Perrot, Valerie
Verzoni, Elena
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[23] Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP
Kubuschok, Boris
Otremba, Burkhard
Welslau, Manfred
Topaly, Julian
Wolff, Thomas
Lenz, Georg
Grau, Michael
da Silva, Larissa Bittencourt
Brueckmann, Ines
Foierl, Tobias
ANNALS OF HEMATOLOGY, 2024, 103 (08) : 3165 - 3178
[24] VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly
Fina, Mariapaola
Tani, Monica
Stefoni, Vittorio
Musuraca, Gerardo
Marchi, Enrica
Pellegrini, Cinzia
Alinari, Lapo
Derenzini, Enrico
Bacci, Francesco
Pileri, Stefano
Baccarani, Michele
Zinzani, Pier Luigi
LEUKEMIA & LYMPHOMA, 2007, 48 (11) : 2167 - 2171
[25] Bendamustine plus Rituximab as Treatment for Elderly Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Vacirca, Jeffrey
Tabbara, Imad
Acs, Peter
Shumaker, Grace
BLOOD, 2010, 116 (21) : 1157 - 1157
[26] Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
Lugtenburg, Pieternella
Avivi, Irit
Berenschot, Henriette
Ilhan, Osman
Marolleau, Jean Pierre
Nagler, Arnon
Rueda, Antonio
Tani, Monica
Turgut, Mehmet
Osborne, Stuart
Smith, Rodney
Pfreundschuh, Michael
HAEMATOLOGICA, 2017, 102 (11) : 1913 - 1922
[27] Prospective non-interventional multicentre observational trial of first-line anti-cancer treatment in patients with metastatic renal cell cancer in Belgium
Cornelis, N.
Vermassen, T.
Schallier, D.
Machiels, J. -P.
Gil, T.
Debruyne, P. R.
D'hondt, R.
Bols, A.
Schrijvers, D.
Mebis, J.
Lumen, N.
Rottey, S.
ACTA CLINICA BELGICA, 2014, 69 (05) : 335 - 340
[28] Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study
Wu, Jian-Qiu
Song, Yong-Ping
Su, Li-Ping
Zhang, Ming-Zhi
Lis, Wei
Hu, Yu
Zhang, Xiao-Hong
Gao, Yu-Huan
Niu, Zuo-Xing
Feng, Ru
Wang, Wei
Peng, Jie-Wen
Li, Xiao-Lin
Ouyang, Xue-Nong
Wu, Chang-Ping
Zhang, Wei-Jing
Zeng, Yun
Xiao, Zhen
Liang, Ying-Min
Zhuang, Yong-Zhi
Wang, Ji-Shi
Sun, Zi-Min
Bai, Hai
Cui, Tong-Jian
Feng, Ji-Feng
CHINESE MEDICAL JOURNAL, 2018, 131 (15) : 1767 - 1775
[29] R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
Al-Sarayfi, Diana
Meeuwes, Frederik O.
Durmaz, Mujde
Issa, Djamila E.
Brouwer, Rolf E.
Beeker, Aart
van Rhenen, Anna
Mutsaers, Pim G. N. J.
Bohmer, Lara H.
van der Poel, Marjolein W. M.
te Boome, Liane
van Meerten, Tom
Chamuleau, Martine E. D.
Zijlstra, Josee M.
Brink, Mirian
Nijland, Marcel
BLOOD CANCER JOURNAL, 2022, 12 (09)
[30] R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
Diana Al-Sarayfi
Frederik O. Meeuwes
Müjde Durmaz
Djamila E. Issa
Rolf E. Brouwer
Aart Beeker
Anna van Rhenen
Pim G. N. J. Mutsaers
Lara H. Böhmer
Marjolein W. M. van der Poel
Liane te Boome
Tom van Meerten
Martine E. D. Chamuleau
Josée M. Zijlstra
Mirian Brink
Marcel Nijland
Blood Cancer Journal, 12

← 1 2 3 4 5 →